Kubigo Tablet SR contains Nitrofurantoin 100 mg, an antibacterial agent primarily used for the treatment and prevention of urinary tract infections (UTIs) caused by susceptible strains of bacteria. Nitrofurantoin acts by inhibiting bacterial enzymes involved in carbohydrate metabolism, thereby interfering with bacterial cell wall synthesis and ultimately leading to bacterial cell death. Kubigo Tablet SR is formulated as a sustained-release preparation to ensure prolonged therapeutic levels of the drug in the urinary tract, enhancing efficacy and improving patient compliance by reducing dosing frequency. It is indicated for acute and chronic infections of the lower urinary tract, including cystitis and pyelonephritis, particularly those caused by Escherichia coli, Staphylococcus saprophyticus, and other common uropathogens. The medication should be used with caution in patients with renal impairment, as reduced renal function may decrease drug excretion and increase the risk of toxicity. Common adverse effects include gastrointestinal disturbances, headache, and hypersensitivity reactions; rare but serious side effects include pulmonary fibrosis and hepatotoxicity. Kubigo Tablet SR is contraindicated in patients with known hypersensitivity to nitrofurantoin or related compounds, and in late pregnancy due to the risk of hemolytic anemia in the newborn. Proper hydration and adherence to prescribed dosing are essential to optimize treatment outcomes.